Pemetrexed (Alimta®): A new antifolate for non-small-cell lung cancer

Research output: Contribution to journalArticlepeer-review

Abstract

Pemetrexed (Alimta®) is a novel multitargeted antifolate that has activity against non-small-cell lung cancer (NSCLC). As a single agent, the response rate is 16%-23%. As second-line therapy, it has a 5% and 14% response rate with pemetrexed in NSCLC patients who have had prior cisplatin or nonplatinum chemotherapy, respectively. Pemetrexed combined with cisplatin has a response rate of 38.9%-44.8%, with a median survival of 8.9-10.9 months. Pemetrexed plus gemcitabine in NSCLC has a response rate of less than 25%. The major toxicity associated with pemetrexed is neutropenia, which may be reduced with vitamin B12 and folate nutritional supplement. Additional studies with pemetrexed in combination with other agents are needed for the treatment of NSCLC patients.

Original languageEnglish (US)
Pages (from-to)S22-S25
JournalClinical lung cancer
Volume3
Issue numberSUPPL. 1
DOIs
StatePublished - Jan 1 2002
Externally publishedYes

Keywords

  • Cisplatin
  • Folate and vitamin B supplement
  • Gemcitabine
  • Multitargeted antifolate

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research

Fingerprint

Dive into the research topics of 'Pemetrexed (Alimta®): A new antifolate for non-small-cell lung cancer'. Together they form a unique fingerprint.

Cite this